Mary Ann Liebert, Inc. has announced the launch of AI in Precision Oncology, an academic, bimonthly peer-reviewed research journal devoted to advancing the application of artificial intelligence (AI) in clinical and precision oncology. With a preview issue scheduled for Fall 2023 and the inaugural issue set to release in early 2024, this groundbreaking publication aims to centralize essential research, reviews, and information on AI within the oncology community, fostering collaboration and driving improvements in patient outcomes.
Led by Editor-in-Chief Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth, the Journal brings together a distinguished team of experts, including David Penberthy, MD, MBA, Associate Professor of Radiation Oncology at Penn State Health; Nikhil Thaker, MD, Chief Medical Informatics Officer at Arizona Oncology; and Scott Penberthy, Managing Director of AI at Google. Together, they will steer the journal's high-profile platform for cutting-edge research, reviews, and front matter that highlights significant advances in the rapidly evolving field of AI in precision oncology. The esteemed Editorial Board features prominent figures like Leroy (Lee) Hood, MD, PhD, from the Institute for Systems Biology, Teri Klein, PhD, from Stanford University, Nihal El Rouby, PhD, from the University of Cincinnati, Jill Kolesar, PhD, from the University of Kentucky, and numerous others.
Dr. Douglas Flora, as Editor-in-Chief of AI in Precision Oncology, envisions the journal as a catalyst for collaboration, research dissemination, and the translation of AI into clinical applications. He expresses his belief that the journal will revolutionize cancer care and enhance patient outcomes through the power of AI.
AI in Precision Oncology welcomes submissions on various topics related to AI in precision oncology, encompassing AI algorithms for cancer detection, diagnosis, and prognosis; AI-based biomarkers for cancer screening and diagnosis; AI-assisted imaging analysis for tumor detection and segmentation; AI-guided treatment planning and personalized therapy; AI-enabled drug discovery and development; machine learning and deep learning in cancer research; natural language processing for electronic health record analysis; and ethical and regulatory issues in AI in oncology.
The journal invites original research articles, systematic reviews, meta-analyses, perspectives on AI in precision oncology, as well as letters to the editor and commentaries addressing current issues in the field. Rigorous peer review by experts ensures the highest standards of scientific rigor and transparency. The editorial team comprises accomplished individuals with diverse expertise in academia, industry, and clinical practice, fostering a comprehensive evaluation process. Pre-submission inquiries are currently being accepted.
The integration of AI in oncology has the potential to revolutionize cancer care, spanning early detection to precision medicine. AI facilitates the analysis of complex data such as genomics, imaging, and electronic health records, leading to improved cancer diagnosis and treatment planning. Additionally, AI aids in predicting treatment responses, identifying new drug targets, and streamlining clinical trials. The scope of the journal encompasses all facets of AI in oncology, from fundamental research to clinical implementation.
As a peer-reviewed platform, AI in Precision Oncology aims to help oncology professionals understand how AI and technology solutions can be applied in an evidence-based, ethical, and thoughtful manner. The journal seeks to promote the responsible and effective use of AI in oncology, benefiting both healthcare providers and patients. Ultimately, it strives to contribute to the development of safer, easier, and more humane cancer care. Interested individuals can sign up for future email alerts for AI in Precision Oncology through the provided link.
Click here to read the original press release.
